Myriad Genetics | MYGN - Ebitda


Myriad Genetics reported $14.3M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Agilent USD 456M 84M Dec/2025
Becton, Dickinson and Co. USD 1.71B 1B Jun/2026
Bio-Rad Laboratories USD 595.3M 1.23B Jun/2026
Bruker USD 143.2M 33.2M Jun/2026
Danaher USD 1.84B 81M Jun/2026
Illumina USD 330M 80M Jun/2026
J&J USD 8.27B 1.08B Mar/2026
Mettler Toledo International USD 322.64M 43.66M Jun/2026
Myriad Genetics USD 14.3M 4M Dec/2025
OraSure Technologies USD -17.7M 4.06M Dec/2025
Pacific Biosciences Of California USD -35.4M 5.78M Sep/2025
Quest Diagnostics USD 648M 91M Jun/2026
Quidel USD 129.3M 20.6M Jun/2026
Repligen USD 43.77M 3.76M Jun/2026
Revvity USD 228.18M 44.73M Jun/2026
Standard Biotools USD -8.01M 7.8M Mar/2026
Thermo Fisher Scientific USD 3.55B 845M Jun/2026
Veracyte USD 43.96M 1.16M Jun/2026
Waters USD 712M 545M Jun/2026